期刊
MOLECULAR THERAPY
卷 19, 期 10, 页码 1769-1779出版社
CELL PRESS
DOI: 10.1038/mt.2011.164
关键词
-
资金
- Louisville Veterans Administration Medical Center (VAMC)
- National Institutes of Health (NIH) [R01CA137037, R01AT004294, R01CA116092, R01CA107181]
- Susan G. Komen Breast Cancer Foundation
In this study, exosomes used to encapsulate curcumin (Exo-cur) or a signal transducer and activator of transcription 3 (Stat3) inhibitor, i.e., JSI124 (Exo-JSI124) were delivered noninvasively to microglia cells via an intranasal route. The results generated from three inflammation-mediated disease models, i.e., a lipopolysaccharide (LPS)-induced brain inflammation model, experimental autoimmune encephalitis and a GL26 brain tumor model, showed that mice treated intranasally with Exocur or Exo-JSI124 are protected from LPS-induced brain inflammation, the progression of myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental autoimmune encephalomyelitis (EAE), and had significantly delayed brain tumor growth in the GL26 tumor model. Intranasal administration of Exo-cur or Exo-JSI124 led to rapid delivery of exosome encapsulated drug to the brain that was selectively taken up by microglial cells, and subsequently induced apoptosis of microglial cells. Our results demonstrate that this strategy may provide a noninvasive and novel therapeutic approach for treating brain inflammatory-related diseases. Received 4 March 2011; accepted 10 July 2011; published online 13 September 2011. doi:10.1038/mt.2011.164
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据